The Cooper Companies enters the week with an unusual split: short sellers have been adding positions aggressively over the past month, yet options traders are among the most bullish they've been all year.
The short interest angle is the more striking development. Short interest has risen roughly 52% over the past month to just under 4% of the free float — a move that took positions from a standing start of around 2.5% to nearly 8 million shares short. The week alone added another 5.2% to that tally. What makes this notable is the speed, not the absolute level; 4% of float is not extreme in isolation, but doubling in a month in a mid-cap health care name without an obvious catalyst demands attention. The borrow market is not particularly stressed by the buildup: availability runs at roughly 1,070% of outstanding short interest, meaning there are more than ten shares available to borrow for every one currently lent out. Cost to borrow has crept up to 0.55% — a four-week high, but still firmly in "easy" territory. This is not a squeeze setup. It looks more like a deliberate fundamental short being constructed at low cost.
Options traders disagree with the bears. The put/call ratio has fallen to 0.55, nearly 1.7 standard deviations below its 20-day average of 0.64, making call positioning relative to puts the most dominant it has been in recent memory. For context, the 52-week low on the PCR is 0.20 and the high is 1.72 — the current reading is well toward the bullish end of that range. The divergence between a rebuilding short position and a call-heavy options book is the week's central tension for COO.
On the Street, the picture is cautious but not negative. Citigroup's Joanne Wuensch raised her target this morning to $76 from $69 while holding a Neutral rating — a notable move given the stock closed Tuesday at $71.89, and it narrows the implied downside to zero. The broader analyst community spent much of early June cutting targets in response to the June 4 earnings print. JP Morgan trimmed to $71, Wells Fargo to $66, while the more constructive names — Stifel, Needham, Baird, Mizuho, and Piper Sandler — all held Buy or Outperform ratings despite lowering their numbers into the $85–$86 range. The consensus mean target sits around $80.57, implying roughly 12% upside from current levels. The bull case rests on Cooper's leading position in specialty contact lenses and eventual margin recovery; the bear case centres on pricing pressure in Asia-Pacific, slower-than-expected fertility market growth, and the uncertainty created by the strategic review of whether to separate CooperVision from CooperSurgical. Valuation is undemanding: the trailing P/E has recovered to roughly 15x on the 30-day move, and EV/EBITDA runs near 12x.
The June 4 earnings print is worth holding in mind for context. COO surged 11.6% the day after that report and held nearly all of those gains across the following week. That was a sharp move in either direction from what the market was pricing — and it came despite a quarter that many analysts described as disappointing on revenue. The next earnings event is scheduled for September 3. The stock has added 6.8% over the past month from its post-earnings base, though it gave back about 1% on Tuesday.
Among correlated peers, RMD had an exceptional week, up 10.7%, while MDT added 3.6%. SYK and GEHC were roughly flat. COO's 0.25% weekly gain looks modest by comparison, suggesting the stock has not fully participated in the broader medical device bid despite its own recovery off the June lows. The short score, at 38.7, has been drifting higher in small increments all week — not alarming, but directionally consistent with the fresh short interest being added. Whether the options market's call-heavy skew or the short sellers' gathering conviction proves correct is what makes the September print the natural focal point for this name.
See the live data behind this article on ORTEX.
Open COO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
